Get the Stockscreener App
8.12
2.92%
0.23
Overview
News
Price History
Option Chain
Financials
Why BHC Down?
Discussions
Forecast
Stock Split
Dividend History
Bausch Health Companies Inc stock is traded at $8.12, with a volume of 909.73K.
It is up +2.92% in the last 24 hours and up +1.00% over the past month.
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
See More
Previous Close:
$7.89
Open:
$7.9
24h Volume:
909.73K
Relative Volume:
0.42
Market Cap:
$2.98B
Revenue:
$9.47B
Net Income/Loss:
$-178.00M
P/E Ratio:
-3.0758
EPS:
-2.64
Net Cash Flow:
$1.01B
1W Performance:
-0.85%
1M Performance:
+1.00%
6M Performance:
+27.67%
1Y Performance:
+17.85%
1-Day Range:
$7.86
$8.14
1-Week Range:
$7.74
$8.215
52-Week Range:
$3.96
$11.46
Bausch Health Companies Inc Stock (BHC) Company Profile
Name
Bausch Health Companies Inc
Sector
Phone
514-744-6792
Address
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Compare BHC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHC
Bausch Health Companies Inc
|
8.12 | 2.98B | 9.47B | -178.00M | 1.01B | -2.64 |
|
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
|
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-02-24 | Downgrade | Piper Sandler | Neutral → Underweight |
| Jul-10-24 | Initiated | Raymond James | Mkt Perform |
| Sep-20-23 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Jul-29-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-29-22 | Downgrade | Truist | Buy → Hold |
| Jul-28-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-13-22 | Resumed | JP Morgan | Overweight |
| Mar-24-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-17-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-22-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-17-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-24-20 | Initiated | Citigroup | Buy |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-22-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-02-19 | Initiated | Goldman | Neutral |
| Oct-25-19 | Initiated | Cowen | Outperform |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Aug-15-19 | Upgrade | TD Securities | Hold → Buy |
| Jul-19-19 | Initiated | Wolfe Research | Outperform |
| Jun-11-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Jan-02-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Nov-05-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-13-18 | Upgrade | Piper Jaffray | Underweight → Neutral |
View All
Bausch Health Companies Inc Stock (BHC) Latest News
Bausch Health Companies Inc. (NYSE:BHC) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Bausch (BHC) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
What is Zacks Research's Estimate for BHC FY2024 Earnings? - MarketBeat
Zacks Research Has Positive View of TSE:BHC FY2024 Earnings - MarketBeat
Traveler's Diarrhea Market Business Strategies, Regional - openPR
Bausch Health Companies (TSE:BHC) Trading Down 0.3%What's Next? - MarketBeat
Scar Treatment Market Detailed In New Research Report 2024 | - openPR
Aesthetic Devices Market in Mexico to Grow by USD 533.06 Million (2024-2028) as AI Impacts Market Trends, Rising Awareness Boosts RevenueTechnavio - Lelezard
LMR Partners LLP Purchases Shares of 400,000 Bausch Health Companies Inc. (NYSE:BHC) - MarketBeat
US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug - Marketscreener.com
Herpes Zoster Oticus Market: Company Profiles, Segment Sizes, - openPR
Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis - AccessWire
Bausch Health's Triple-Action Acne Treatment CABTREO Gains Key Canadian Approvals | BHC Stock News - StockTitan
Common Warts Treatment Market Trade Analysis and Statistical - openPR
Underactive Bladder Treatment Market Expected to Reach Huge - openPR
Genital Herpes Treatment Market Global Share, Trends, Business - openPR
Varicella Zoster (HHV-3) Infections Treatment Market Share, - openPR
Vitrectomy Devices Market is expected to reach US$ 2121.3 - openPR
22q11.2 Deletion Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Nobias Therapeutics, Zynerba Pharma, Bausch Health Americas - The Globe and Mail
Actinic Keratosis Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyze | Bausch Health Companies, Sandoz Pharma, Athenex, Almirall, Vidac Pharma, G&E Herbal Biotech - Barchart
Periodontal Therapeutics Market to Grow at a Promising CAGR - openPR
Bausch Health Companies: Top 25 Undervalued Toronto Stock Exchange Stocks (BHC) - Barchart
Myopia and Presbyopia Treatment Market to Grow by USD 9.76 Billion from 2024-2028, as Rising Prevalence Drives Demand with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve
Are Medical Stocks Lagging Bausch Health (BHC) This Year? - MSN
Body Contouring Treatments Market to Hit USD 2.58 Billion by 2029 with 10.0% CAGR | MarketsandMarkets™ - The Manila Times
Eye Health Supplements Market Trends and Growth Projections - openPR
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve
189,000 Shares in Bausch Health Companies Inc. (NYSE:BHC) Bought by Intact Investment Management Inc. - MarketBeat
Bausch Health Companies' SWOT analysis: debt woes cloud strong Q3 stock performance - Investing.com
Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales - MSN
Bausch Health Companies Inc. (NYSE:BHC) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Bausch Health secures $400 million loan amendment - Investing.com
Bausch Health secures $400 million loan amendment By Investing.com - Investing.com UK
Bausch Health Companies (NYSE:BHC) Price Target Raised to $11.00 at Royal Bank of Canada - MarketBeat
Bausch Health Companies Inc. (NYSE:BHC) Q3 2024 Earnings Call Transcript - Insider Monkey
Bausch Health Companies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Bausch Health stock outlook lifted as RBC cites robust Q3 growth and tax benefits - Investing.com
Traders Purchase High Volume of Bausch Health Companies Put Options (NYSE:BHC) - MarketBeat
Toronto Stocks Drop, Canada's GDP Flat in August; Bausch Health Rises on 3Q Beat - Marketscreener.com
Bausch Health Shares Rise on FY Outlook Upgrade, 3Q Beat - MarketWatch
Bausch Health Companies (NYSE:BHC) Trading 8.7% Higher on Better-Than-Expected Earnings - MarketBeat
Bausch Health Companies (TSE:BHC) Stock Price Up 8.4% Following Earnings Beat - MarketBeat
BHCBausch Health Companies Inc. Latest Stock News & Market Updates - StockTitan
Bausch: Q3 Earnings Snapshot - Houston Chronicle
Bausch Health Reports Growth Amid Improved Financials - TipRanks
Compared to Estimates, Bausch (BHC) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Bausch Health (BHC) Beats Q3 Earnings and Revenue Estimates - Yahoo Finance
Bausch Health Companies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Bausch Health Announces Third Quarter 2024 Results - AccessWire
Gastroparesis Treatment Market Top Trends and Growth Analysis: - openPR
Bausch Health Companies Inc Stock (BHC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.83%
1.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):